| Literature DB >> 27679778 |
Maria Pontillo1, Franco De Crescenzo1, Stefano Vicari1, Maria Laura Pucciarini1, Roberto Averna1, Ornella Santonastaso1, Marco Armando1.
Abstract
AIM: To provide an updated of recent findings about efficacy of cognitive-behavior therapy (CBT) in reduction of command hallucinations.Entities:
Keywords: Auditory hallucinations; Cognitive-behavior therapy; Distress; Functional impairment; Psychotic disorder; Schizophrenia; Treatment
Year: 2016 PMID: 27679778 PMCID: PMC5031939 DOI: 10.5498/wjp.v6.i3.372
Source DB: PubMed Journal: World J Psychiatry ISSN: 2220-3206
Figure 1Flow chart of literature review. AHs: Auditory hallucinations; CBT: Cognitive-behavior therapy; RCT: Randomized clinical trial.
Randomized clinical trials of cognitive behavioral therapy for auditory hallucinations
| Shawyer et al[ | RCT | (1) diagnosis of schizophrenia or related condition based on DSM-IV criteria (2) command hallucinations within the previous 6 mo that caused distress or dysfunction despite treatment with antipsychotic medication at therapeutic doses | Assessor-rated degree of compliance with harmful command hallucinations on a scale of 0-7 Self-rated confidence to resist obeying harmful commands and confidence in coping with general commands on a scale of 0-100 PANSS Modified GAF PSYRATS Quality of Life Enjoyment and Satisfaction Questionnaire Client Satisfaction Questionnaire VAAS BAVQ-R 8-item self-report Insight Scale RSQ | Randomized to 15 sessions of the intervention “TORCH” or the control, Befriending. A sub-sample of 17 participants was randomized to a waitlist control before being allocated to TORCH or Befriending Pharmacological treatment: Chlorpromazine equivalent dose (mg) Mean = 742.9 SD = 388.7 | Confidence to resist harmful CHs ( | 6-mo | |
| Birchwood et al[ | RCT | (1) ICD-10 schizophrenia, schizoaffective, or mood disorders, under care of a clinical team (2) history of harmful command hallucinations of at least 6 mo duration with recent (< 9 mo) history of harm to self, others or major social transgressions as a result of the commands (full or partial compliance); or harmful command hallucinations where the individual is distressed and appeasing the powerful voice | VCS VPD Personal knowledge questionnaire/omniscience scale BAVQ-R PSYRATS Calgary Depression Rating Scale for Schizophrenia Beck Hopeleness Scale Beck Scale for Suicidal Ideation PANSS | Randomized to cognitive Therapy for command Hallucinations + treatment as usual or treatment as usual alone Adherence to cognitive therapy was excellent: only 12 (12%) of 98 participants not attending any sessions, and 79 (81%) completing the therapy (all manualised elements) Pharmacological treatment: Olanzapine equivalents dose (mg) 25.79 (SD: 21.73). | RSQ ( | 18-mo |
AHs: Auditory hallucinations; BAVQ-R: Beliefs about the voices questionnaire-revised; CHs: Command hallucinations; GAF: Global assessment of functioning scale; n.s.: Not significant; PANSS: Positive and negative syndrome scale; RCT: Randomized clinical trial; PSYRATS: Psychotic symptom rating scale; RSQ: Recovery style questionnaire; VAAS: Voices acceptance and action scale; VCS: Voice compliance scale; VPD: Voice power differential scale.
Non randomized clinical trials of cognitive behavioral therapy for auditory hallucinations
| Zanello et al[ | Naturalistic Study | (1) Diagnosis of a schizophrenia or schizoaffective disorder (2) Current AHs in the form of voices, occurring at least once per week | Reduction of AHs: BPRS Total symptom severity without AHs: BPRS | 7 sessions of CBT based upon the program “Voice Group” of Wikes et al 1999 Pharmacological treatment: New antipsychotic Combined antipsychotic Anxiolytic, mood stabilizer, hypnotic or antidepressant medication Dosage: Changed when clinically required | Decrease in the hallucinations item score of Bprs ( | 6-mo | |
| Thomas et al[ | Non-RCT Open trial | 1) Diagnosis of a schizophrenia or schizoaffective disorder (2) Current AHs in the form of voices, occurring at least once per week (3) Voices associated with significant subjective distress (4) History of voices for at least one year; and (5) currently prescribed antipsychotic medication | Correlation between PSYRATS, PANSS, SAI and Outcome Main Outcome measure: Improvement of five points of more on the PSYSTRATS | 24 sessions of CBT based upon the manual of Fowler et al (1995) Pharmacological treatment: Chlorpromazine-equivalent pre-treatment: M = 793.1 mg, SD = 468.6 mg; post–treatment: M = 768.1 mg, SD = 473.8 mg | Only negative symptoms showed a statistically correlation with outcome (rpb = -0.60; | None | |
| Mortan et al[ | Pilot study | (1) Criteria for schizophrenia or schizoaffective based on DSM-IV-R (SCID I) (2) At least 1 psychotic attack with hospitalization (3) Ongoing AHs (4) Use of oral and injectable antipsychotic | Presence of Positive Symptoms: SAPS Presence of Negative Symptoms: SANS Comorbid symptoms: BDI HDI | 9-10 sessions of CBT upon the manual of Morrison, 2002, Goldberg, 2007) Pharmacological treatment: Oral and injectable antipsychotic medication | Difference between pre-treatment and post-treatment Treatment goup: SAPS hallucination subscale score ( | 1-yr post-treatment follow-up | |
| Hutton et al[ | Single case, An 18-year-old man | Case report | Criteria for schizophrenia spectrum disorder based on DSM-IV Symptoms and psychosocial functioning: GAF; BPRS; Clinical questionnaire | Positive Symptoms: PSYRATS/CAARMS Beliefs about control of AHs: IVI | Brief CBT upon the mindfulness approach Pharmacological treatment: None | Pre-treatment: IVI score: 62 Post treatment: IVI score 2 The frequency and duration of AHs had reduced to zero | 1, 3, 4, 9 mo post therapy |
| Dannahy et al[ | Pilot study | The individual had been experiencing treatment-resistant and subjectively distressing voices for at least the preceding 2 yr, with the voice-distress rated at 3 or greater on at least one of the two PSYRATS voice-distress items | Primary outcome measure: Improve general psychosocial well-being (CORE-OM); Secondary measures: Reduce distress and perceived voice-control; Evaluate the relationship with voice (VAY) | Group person-based cognitive Therapy (PBCT) conducted over 8-12 sessions based upon the manual of Chadwick et al (2006) Pharmacological treatment: Standard psychiatric care Group person-based cognitive Therapy (PBCT) conducted over 8-12 sessions based upon the manual of Chadwick et al (2006) Pharmacological treatment: Standard psychiatric care | CORE-OM Total score: Post-group: 1.90 | 1 mo | |
| Gottlieb et al[ | Pilot study | (1) Criteria for schizophrenia, schizoaffective disorder, or psychosis, NOS based on DSM-IV (2) At least “moderate” level of AHs severity over the past week (BPRS Hallucinations item 4 or higher); (3) Between the ages of 18-65; (4) No exposure to CBTp within the past 3 yr (5) No current suicidal ideation or hospitalization within the past month (6) Taking a stable dose of an antipsychotic medication for at least one month; (7) No active substance abuse/dependence (8) MMSE score ≥ 24) | Primary outcomes: Reduce the frequency, intensity, loudness, associated distress, perceived degree of controllability of, and interference from AHs (PSYRATS) Secondary outcomes: Evaluate beliefs about AHs (BAVQ-R); Evaluate overall psychopathology (BPRS), and depression (BDI-II) | Web-based cognitive-behavioral therapy for AHs: - 10 session: - psychoeducational video tutorials - games - interactive exercises - social network to examine the coping strategies of other users. Pharmacological treatment: stable dose of antipsychotic medication for at least one month | Significant reductions from baseline to post-treatment in several measures of AHs and in overall psychopathology on the BPRS: PSYRATS AHs subscale total: | None |
P < 0.001. BPRS: Brief psychiatric rating scale; PSYRATS: Psychotic symptom rating scale; PANSS: The positive and negative syndrome scale for schizophrenia; SAI: The Schedule for the Assessment of Insight; SCID-I: Structured Clinical Interview for DSM; SAPS: Scale for the assessment of positive symptoms; SANS: Scale for the assessment of negative symptoms; BDI-II: The Back Depression Inventory II; HDI: Hamilton depression inventory; CAARMS: Comprehensive Assessment of At-Risk Mental States; GAF: Global Assessment of functioning; IVI: Interpretation Voices of Inventory; CORE-OM: Clinical outcomes in routine evaluation-outcome measure; VAY: Voice and You; BAVQ-R: The Belief about Voices Questionnaire-Revised; MMSE: Mini Mental State Examination; AHs: Auditory hallucinations.